Table 2.

Impact of calcilytic NPS 2143 on fAβ_25–35-evoked cumulative 0-h-to-96-h secretion/shedding of neuroinflammatory agents from NAHAs.

	Treatments	Cumulative Secretion §	% Changes vs. CTR	% Changes vs. fAβ25–35
IL-6	CTR	502.1 ± 39.6
	fAβ25–35	905.6 ± 48.4	+80.4 *
	fAβ25–35 +NPS 2143	576.9 ± 41.0	+14.9	−81.5 *
s-ICAM-1	CTR	30.6 ± 2.3
	fAβ25–35	59.7 ± 2.7	+95.1 *
	fAβ25–35 + NPS 2143	41 ± 2.6	+34.0 *	−64.3 *
RANTES	CTR	42.9 ± 13.3
	fAβ25–35	226 ± 17.2	+426.8 *
	fAβ25–35 + NPS 2143	149.3 ± 7.4	+248.0 *	−41.9 *
MCP-2	CTR	185.9 ± 29.3
	fAβ25–35	6897.9 ± 248	+3611.0 *
	fAβ25–35 + NPS 2143	2717.6 ± 320	+1361.9 *	−62.3 *

^§ Expressed as mean values ± SEM of the areas under the respective 0 h-to-96 h curves. *, p < 0.05. CTR, untreated controls.